Analysts Set Certara, Inc. (NASDAQ:CERT) PT at $12.91

Certara, Inc. (NASDAQ:CERT) has been given an average recommendation of “Moderate Buy” by the fifteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $12.9091.

Several equities analysts have issued reports on the stock. BMO Capital Markets initiated coverage on shares of Certara in a research report on Thursday, November 13th. They issued a “market perform” rating and a $9.00 target price on the stock. Morgan Stanley reduced their target price on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. Stephens lowered their price target on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, December 12th. Craig Hallum initiated coverage on Certara in a research note on Monday, September 29th. They set a “buy” rating and a $16.00 price target on the stock. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Certara in a research note on Monday.

Institutional Trading of Certara

Institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. lifted its holdings in Certara by 5.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 797,610 shares of the company’s stock worth $7,896,000 after buying an additional 40,218 shares in the last quarter. Invesco Ltd. increased its position in shares of Certara by 0.3% during the first quarter. Invesco Ltd. now owns 394,037 shares of the company’s stock worth $3,901,000 after acquiring an additional 1,285 shares during the last quarter. Nuveen LLC acquired a new position in shares of Certara in the first quarter worth about $2,676,000. Northern Trust Corp boosted its holdings in Certara by 4.5% in the first quarter. Northern Trust Corp now owns 916,299 shares of the company’s stock valued at $9,071,000 after purchasing an additional 39,289 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its holdings in Certara by 13.6% in the first quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock valued at $42,526,000 after purchasing an additional 515,911 shares during the last quarter. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Stock Down 0.2%

NASDAQ:CERT opened at $8.89 on Wednesday. The company’s 50-day simple moving average is $9.72 and its 200-day simple moving average is $10.69. The stock has a market capitalization of $1.42 billion, a P/E ratio of 127.00 and a beta of 1.46. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. Certara has a fifty-two week low of $8.02 and a fifty-two week high of $15.69.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The business had revenue of $104.62 million for the quarter, compared to analyst estimates of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same quarter in the previous year, the firm earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, equities analysts anticipate that Certara will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.